The COVID-19 pandemic has developed offer chain gaps in essential drug products and solutions, in particular individuals necessary for the most critical patients in intense treatment units across the nation.
DARPA (Defense State-of-the-art Analysis Challenge Company) has chosen Continuity Pharma, a Purdue University-affiliated enterprise, to create continual manufacturing technological know-how. The business was chosen for a $1.5 million grant.
DARPA has established a aggressive assessment process, awarding grant funding to providers presenting advanced manufacturing systems.
Continuity Pharma’s mission is to implement novel constant manufacturing abilities to reshore generic drug products and solutions to the U.S., with distinct concentration on prescription drugs in limited provide.
We are thrilled to be picked by DARPA to more our growth initiatives. We are one phase nearer to making certain the availability of vital medicines to sufferers in have to have. It is an interesting time for Continuity Pharma.”
David Thompson, Purdue professor of natural chemistry and co-founder and chief scientific officer at Continuity
Grant particulars consist of development funding above the next 24 months, with extra funding for commercialization in the subsequent 12 months. Target parts include capabilities for various API production in the Built-in Ongoing Producing Technique, with shown efficiencies for swift changeover and production efficiencies.
Continuity Pharma leaders are working with Purdue Analysis Basis officers to safe further lab room in Purdue Research Park in West Lafayette.